 |
|
Beta-blockers reduce mortality in patients with COPD after vascular surgery
October 01, 2008In the first study to directly examine the effects of beta-blockers on surgical patients with chronic obstructive pulmonary disease (COPD), researchers have found that, contrary to previous thought, beta-blockers significantly reduce mortality in COPD patients.
"Patients with COPD frequently have unrecognized, atherosclerotic disease. This is also a major cause for late morbidity and mortality," said principle investigator Don Poldermans, M.D., Ph.D., of the Erasmus Medical Center in Rotterdam, the Netherlands.
The results were published in the first issue for October of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.
Clinical trials on the benefits of using preoperative beta-blockers to lower the risk of cardiovascular events in patients undergoing noncardiac surgery have yielded inconsistent results. Recent guidelines from the American Heart Association, however, recommend beta-blockers before noncardiac surgery for patients who are at high risk for or who have known cardiovascular disease.
But patients with COPD, who have an increased risk of cardiovascular disease, often do not receive preoperative beta-blockers because of concerns that the drugs will aggravate bronchospasm and worsen their airway obstruction. Moreover, the benefits of beta-blockers have not been examined in a population of patients with COPD undergoing noncardiac disease.
To determine the effect of beta-blockers on COPD patients undergoing vascular surgery, the researchers evaluated the mortality outcomes of more than 3,000 consecutive patients who underwent vascular surgery at the Erasmus Medical Center in Rotterdam between 1990 and 2006. They specifically looked at the effect of a low dose of beta-blockers (less than 25 percent maximum recommended therapeutic dose) versus an "intensified" dosage (more than 25 percent maximum recommended therapeutic dose).
Of the 3,371 patients evaluated, 31 percent-more than 1000-received cardio-selective beta-blockers at their initial hospitalization. There was no apparent clinical differences between the patients with COPD- 39 percent of the entire study sample- and those without in terms of the likelihood of them receiving beta-blockers.
They found that cardio-selective beta-blockers were independently associated with reduced 30-day mortality in both patients with and without COPD. In the 30 days after surgery, COPD patients did not receive beta-blockers were twice as likely to die as those who did (eight percent versus four percent.) Over the long term, a similar trend, though not statistically significant, emerged. During the follow-up period, 40 percent of COPD patients on beta-blockers died, whereas 67 percent who were not on beta-blockers died.
"What was observed in the population, beta blockers, especially, cardioselective beta blockers like bisoprolol are well tolerated by COPD patients without inducing respiratory adverse effects. More importantly, they improve outcome, by preventing late cardiac events, a major cause for late morbidity and mortality," said Dr. Poldermans.
They also found that in COPD patients, an intensified dose, but not a low dose, of beta-blockers was associated with reduced 30-day mortality, but in the long term, both intensified and low dosages were associated with similar reductions in mortality. In patients without COPD, both low and intensified doses were associated with reduced mortality in 30-days but in the long term, only the intensified dose was associated with a nonsignificant trend in reduced mortality.
"We found that an intensified dosing regimen appeared to be superior to low-dose therapy in terms of its impact on 30-day mortality," wrote Dr. Poldermans. "We [demonstrated] among a large group of well-characterized patients with COPD-that beta-blockers were safe and beneficial in prolonging survival after major vascular surgery."
"The indications of our findings are that a high-dose might be preferred in the COPD population," said Dr. Poldermans. "The safety of cardioselective beta blockers in the COPD population will support their use."
These findings demonstrate that carefully selected patients with COPD can tolerate cardioselective beta-blockers without experiencing respiratory complications. They also show that COPD patients may be protected by beta-blocker therapy from cardiovascular complications of surgery, such as myocardial infarction. These findings need to be put in context with the recent POISE (Perioperative Ischemic Evaluation) study that demonstrated higher mortality among general populations of patients - those with and without COPD - treated with preoperative beta-blockers.
Dr. John E. Heffner, past president of ATS and Garnjobst Chair at Providence Portland Medical Center, observed that "the jury remains out regarding the utility of preoperative beta-blockers for all patients at risk of cardiovascular complications from noncardiac surgery. But this study suggests that carefully selected patients with COPD, which is an extreme risk factor for cardiovascular disease, at best may benefit but at least appear to tolerate cardioselective beta-blocker therapy. "
American Thoracic Society
Clinical trials on the benefits of using preoperative beta-blockers to lower the risk of cardiovascular events in patients undergoing noncardiac surgery have yielded inconsistent results. Recent guidelines from the American Heart Association, however, recommend beta-blockers before noncardiac surgery for patients who are at high risk for or who have known cardiovascular disease.
But patients with COPD, who have an increased risk of cardiovascular disease, often do not receive preoperative beta-blockers because of concerns that the drugs will aggravate bronchospasm and worsen their airway obstruction. Moreover, the benefits of beta-blockers have not been examined in a population of patients with COPD undergoing noncardiac disease.
To determine the effect of beta-blockers on COPD patients undergoing vascular surgery, the researchers evaluated the mortality outcomes of more than 3,000 consecutive patients who underwent vascular surgery at the Erasmus Medical Center in Rotterdam between 1990 and 2006. They specifically looked at the effect of a low dose of beta-blockers (less than 25 percent maximum recommended therapeutic dose) versus an "intensified" dosage (more than 25 percent maximum recommended therapeutic dose).
Of the 3,371 patients evaluated, 31 percent-more than 1000-received cardio-selective beta-blockers at their initial hospitalization. There was no apparent clinical differences between the patients with COPD- 39 percent of the entire study sample- and those without in terms of the likelihood of them receiving beta-blockers.
They found that cardio-selective beta-blockers were independently associated with reduced 30-day mortality in both patients with and without COPD. In the 30 days after surgery, COPD patients did not receive beta-blockers were twice as likely to die as those who did (eight percent versus four percent.) Over the long term, a similar trend, though not statistically significant, emerged. During the follow-up period, 40 percent of COPD patients on beta-blockers died, whereas 67 percent who were not on beta-blockers died.
"What was observed in the population, beta blockers, especially, cardioselective beta blockers like bisoprolol are well tolerated by COPD patients without inducing respiratory adverse effects. More importantly, they improve outcome, by preventing late cardiac events, a major cause for late morbidity and mortality," said Dr. Poldermans.
They also found that in COPD patients, an intensified dose, but not a low dose, of beta-blockers was associated with reduced 30-day mortality, but in the long term, both intensified and low dosages were associated with similar reductions in mortality. In patients without COPD, both low and intensified doses were associated with reduced mortality in 30-days but in the long term, only the intensified dose was associated with a nonsignificant trend in reduced mortality.
"We found that an intensified dosing regimen appeared to be superior to low-dose therapy in terms of its impact on 30-day mortality," wrote Dr. Poldermans. "We [demonstrated] among a large group of well-characterized patients with COPD-that beta-blockers were safe and beneficial in prolonging survival after major vascular surgery."
"The indications of our findings are that a high-dose might be preferred in the COPD population," said Dr. Poldermans. "The safety of cardioselective beta blockers in the COPD population will support their use."
These findings demonstrate that carefully selected patients with COPD can tolerate cardioselective beta-blockers without experiencing respiratory complications. They also show that COPD patients may be protected by beta-blocker therapy from cardiovascular complications of surgery, such as myocardial infarction. These findings need to be put in context with the recent POISE (Perioperative Ischemic Evaluation) study that demonstrated higher mortality among general populations of patients - those with and without COPD - treated with preoperative beta-blockers.
Dr. John E. Heffner, past president of ATS and Garnjobst Chair at Providence Portland Medical Center, observed that "the jury remains out regarding the utility of preoperative beta-blockers for all patients at risk of cardiovascular complications from noncardiac surgery. But this study suggests that carefully selected patients with COPD, which is an extreme risk factor for cardiovascular disease, at best may benefit but at least appear to tolerate cardioselective beta-blocker therapy. "
American Thoracic Society
Vascular Surgery Current Events and Vascular Surgery News RSSHuman embryonic stem cell secretions minimized tissue injury after heart attack
A novel way to improve survival and recovery rate after a heart attack was reported in the journal Stem Cell Research by scientists at Singapore's Institute of Medical Biology (IMB) and Bioprocessing Technology Institute (BTI) and The Netherlands' University Medical Center Utrecht.
Gene is likely cause of stroke-inducing vascular malformations
UCSF scientists have discovered that a gene controlling whether blood vessels differentiate into arteries or veins during embryonic development is linked to a vascular disorder in the brain that causes stroke.
NYC first: Complex aneurysm treated using new fenestrated endograft stent
In a New York City metro-area first, a 93-year-old Bronx man underwent implantation of a new stent graft at NewYork-Presbyterian Hospital, the only center on the Eastern Seaboard with access to this investigational device.
Damaged veins heal faster with heparin treatment, laboratory study finds
A commonly used medication that prevents blood clots from forming may also prevent existing clots from damaging delicate vein walls - and may accelerate healing in a clot-damaged area of vein wall, according to new research from the University of Michigan Cardiovascular Center.
Mesothelin engineered on virus-like particles provides treatment clues for pancreatic cancer
New understanding of a protein that spurs the growth of pancreatic cancer could lead to a new vaccine against the deadly disease, said researchers at Baylor College of Medicine in Houston in a report appearing in the current edition of the journal Molecular Cancer Therapeutics.
Vascular surgeons ask, what's next for carotid artery stenting?
A procedure called carotid artery stenting (CAS) has emerged as a minimally invasive alternative to surgery, called carotid endarterectomy (CEA), for patients with dangerous narrowing of the arteries supplying blood to the brain.
Arterial vascular disease underdiagnosed, undertreated in older US women
Though arterial vascular disease is widespread and often deadly among older American women, doctors too often fail to spot and treat it, according to a new report by a team of vascular surgeons from the Columbia University Medical Center and Weill Cornell Medical College campuses of NewYork-Presbyterian Hospital.
Life-threatening gene defect located by UT-Houston researchers
A research team led by scientists at The University of Texas Medical School at Houston has identified a defective gene that affects vascular smooth-muscle cells in people who suffer from hereditary thoracic aortic disease, which can kill victims with little warning in the prime of their lives.
Research sheds light on carotid artery stenting risk in elderly
Dr. Hernan Bazan, Assistant Professor of Surgery, Section of Vascular Surgery, at Louisiana State University Health Sciences Center New Orleans' School of Medicine, is the lead author of a research paper which may help physicians decide which patients with carotid artery occlusive disease should have carotid surgery or carotid stenting.
UCLA doctor develops new technique to treat varicose veins
Dr. Peter Lawrence, UCLA's chief of vascular surgery, picks up size 7 crochet hooks from a fabric store - not to make sweaters or scarves but to use in a new technique he has developed to treat varicose veins.
More Vascular Surgery Current Events and Vascular Surgery News Articles
 | Atlas Of Vascular Surgery by Christopher Zarins, Bruce Gewertz Exceptional, step-by-step illustrations and descriptions provide crystal-clear guidance on the most commonly performed vascular surgical procedures. The new 2nd Edition of this well-respected title features comprehensive updates throughout to reflect the newest advances, particularly the explosion in endovascular surgery. In addition, new section introductions summarize indications, preoperative... |
 | Anatomic Exposures in Vascular Surgery by R. James Valentine, Gary G Wind Univ. of Texas Southwestern Medical Center, Dallas. Text is designed to convey the clinical anatomy of the blood vessels through high-quality illustrations. Presents precise key anatomic relationships necessary to understand the vascular pattern in all areas of the body. The chapters are divided into anatomic overview and surgical approach sections. Previous edition:... |
 | Clinical Scenarios in Vascular Surgery (Clinical Scenarios in Surgery Series) This unique case-based review of vascular surgery offers excellent preparation for oral board examinations, which emphasize both general knowledge and case management. The book presents 76 cases covering the range of vascular disorders that surgeons treat and is structured to reflect the surgeon's decision-making process. Each case begins with a patient presentation and imaging studies or... |
 | Vascular Surgery, 2-vol set by Robert B. Rutherford This definitive 2-volume set provides encyclo¬pedic, authoritative coverage of all aspects of vascular surgery. The exhaus¬tively revised and completely updated 6th Edition incorporates greater coverage of endovascular applications through¬out, along with fresh approaches to key areas such as vascular access, imaging, and non-operative man¬agement. In addition, it is now available as a... |
 | Handbook of Patient Care in Vascular Diseases (Lippincott Williams & Wilkins Handbook) by Todd E Rasmussen, W. Darrin Clouse, Britt H Tonnessen Completely revised by a team of new authors with expertise in endovascular procedures, this handbook is a quick reference for the effective treatment of patients with common arterial and venous diseases. In concise outline format, the book covers all major vascular disorders, including peripheral vascular diseases, and emphasizes patient management issues rather than step-by-step surgical... |
 | Vascular Surgery e-dition: Text with Continually Updated Online Reference, 2-Volume Set by Robert B. Rutherford This definitive 2-volume set provides encyclo¬pedic, authoritative coverage of all aspects of vascular surgery. The exhaus¬tively revised and completely updated 6th Edition incorporates greater coverage of endovascular applications through¬out, along with fresh approaches to key areas such as vascular access, imaging, and non-operative man¬agement. In addition, it is now available as a... |
 | Emergency Vascular Surgery: A Practical Guide by Eric Wahlberg, Pär Olofsson, Jerry Goldstone "Emergency Vascular Surgery" provides detailed guidelines to any physician treating patients with emergency vascular disorders, such as ruptured abdominal aortic aneurysms, acute limb ischemia, vascular trauma, iatrogenic vascular injuries and complications to vascular surgery. It provides an introduction to vascular surgical operations and focuses on how to manage patients from the emergency... |
 | Vascular Surgery (Springer Surgery Atlas Series) This Vascular Surgery Atlas is a 'How to' book that allows the reader to focus on the technical aspects of the most commonly performed vascular procedures. The book is edited by two seasoned vascular surgeons with a well established experience in surgical education. The authors have been selected from both sides of the Atlantic to provide the expertise necessary to cover the various... |
 | Vascular Surgery: Cases, Questions and Commentaries This updated and revised second edition of "Vascular Surgery: Cases, Questions and Commentaries" provides a thorough overview of the management principles of clinical cases in vascular surgery. It also summarizes all the relevant topics the vascular trainee is expected to be familiar with. With an international panel of contributors, this book familiarizes the reader quickly with day-to-day... |
 | Vascular and Endovascular Surgery: A Comprehensive Review, Textbook with CD-ROM by Wesley Moore This indispensable certification and recertification preparation source presents a comprehensive and up-to-date review of vascular surgery and a superb refresher on the state of today’s practice. International experts cover every aspect of the field—from the basics to the latest developments—in an easy-to-read, user-friendly format. Every chapter offers a complete summary of a key topic in... |
| © 2009 BrightSurf.com |